Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biomarkers in the ovary

A Berchuck1

  • 1Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA.

Journal of Cellular Biochemistry. Supplement
|January 1, 1995
PubMed
Summary

Genetic alterations in ovarian cancer, including oncogenes like HER-2/neu and tumor suppressor genes such as p53 and BRCA1, are key markers of malignant transformation and disease progression. Understanding these genetic changes is crucial for diagnosis and treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic gene expression signature for high-grade serous ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Gynecologic oncology·2020
Same author

LIFETIME RISK OF OVARIAN CANCER BASED ON ENDOMETRIOSIS AND OTHER RISK FACTORS: IGCS-0014 06. Ovarian Cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2015
Same author

Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC).

Journal of internal medicine·2012
Same author

Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.

British journal of cancer·2009
Same author

MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.

British journal of cancer·2009

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancers exhibit alterations in oncogenes and tumor suppressor genes.
  • These genetic changes serve as crucial markers for malignant transformation.
  • Specific genes like HER-2/neu, K-ras, c-myc, p53, and BRCA1 are frequently implicated.

Purpose of the Study:

  • To review genetic alterations in ovarian cancer.
  • To discuss the role of oncogenes and tumor suppressor genes as biomarkers.
  • To explore the implications of these genetic changes in sporadic and hereditary ovarian cancers.

Main Methods:

  • Literature review of studies on ovarian cancer genetics.
  • Analysis of gene expression and mutation data.
  • Correlation of genetic alterations with clinical outcomes and tumor types.

Main Results:

  • HER-2/neu overexpression (30%) correlates with poor survival.
  • K-ras mutations are found in mucinous and borderline ovarian tumors.
  • c-myc amplification (30%) is common in serous cancers.
  • p53 mutations occur in 50% of advanced and 15% of early-stage ovarian cancers.
  • BRCA1 mutations are linked to hereditary breast and ovarian cancer with early onset.

Conclusions:

  • Acquired genetic alterations are characteristic of sporadic ovarian cancers.
  • Inherited defects, such as BRCA1 mutations, account for a subset of hereditary ovarian cancers.
  • Further research is needed to determine the exact contribution of BRCA1 to hereditary ovarian cancer.

Related Experiment Videos